Tren Mix 200 mg — Vedi Pharma

Tren Mix 200 mg Vedi Pharma

Vedi Pharma

€65,00

In Stock (100 available)

Tren Mix 200 mg Vedi Pharma (200 mg) — Vedi Pharma presents this pharmaceutical-grade compound — this Trenbolone blend combines multiple esters (typically Acetate, Ena…

100 in stock

5+ −10%

10+ −15% Best price

Third-Party Lab Report HPLC verified

CoA available on request — email support@vitalquests.org with the batch code from your vial.

HPLC TestedBatch report available

No Labels on BoxPlain brown parcel

Pay the CourierCash on delivery only

Ships TodayOrder before 14:00

€85+ = free shipping

EU warehouse — no customs, no delays

Tracked via DHL / DPD / InPost

Description

This Vedi Pharma trenbolone acetate at 200 mg delivers the fastest trenbolone ester available. Effects noticeable within 48 hours; clearance quick if side-effects (trensomnia, night sweats) require withdrawal. Not a beginner compound — testosterone base required.

Key Benefits

Multi-ester 19-nor trenbolone — acute kick + sustained coverage
Typical mix: acetate + enanthate + hexahydrobenzylcarbonate
Injection frequency every 3–4 days sufficient
Active molecule identical to single-ester tren at AR level
Same side-effect burden as standalone tren — blend isn’t softer
Each unit dosed at 200 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 150–300 mg/week split across 2–3 injections. The acetate fraction peaks within a day while longer esters build steady-state over 3–4 weeks. Cycles 10–12 weeks.

How It Works

Blend of trenbolone acetate, enanthate, and hexahydrobenzylcarbonate (parabolan) — all three are 19-nor derivatives with the same extreme AR affinity as single-ester trenbolone. Progestagenic. The blend provides staggered release: acetate in ~24 h, enanthate ~7 days, hexa ~10 days. At the receptor level the active molecule is identical across esters.

Pharmacokinetics

Composite release profile. Faster kick-in than pure enanthate, flatter serum than pure acetate. Injection frequency every 3–4 days adequate. Steady-state in 3–4 weeks.

Potential Side Effects

Identical to single-ester tren: prolactin rise, night sweats, insomnia, CV stress, aggression. Caber 0.25 mg 2×/week mandatory. Bloodwork including prolactin at week 6.

Cycle & Stacking Guide

Cutting and recomp cycles 10–12 weeks. Test E 300–500 mg/week + tren blend 200–300 mg/week. Attention to sleep, resting HR, and lipids throughout. Not for first or second cycles.

Manufacturer Notes

Vedi Pharma ships injectables in tamper-evident 10 ml vials with GMP-compliant batch numbering.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Tren Mix 200 mg Vedi Pharma”

2D structural representation · PubChem CID 24822 ↗

Chemical Identity
#	CAS Registry Number	`10161-34-9`
Σ	IUPAC Name	[(8S,13S,14S,17S)-13-methyl-3-oxo-2,3,6,7,8,14-hexahydro-1H-cyclopenta[a]phenanthrene-17-yl] acetate
F	Molecular Formula	C₂₀H₂₄O₃
M	Molecular Weight	312.41 g/mol
⌬	SMILES	`CC(=O)O[C@@H]1CC[C@@H]2C3=CC=C4CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C`
⊞	InChIKey	`FNYKCQMZFXUVMA-LKBHZCJUSA-N`
△	Melting Point	96-97 °C
≋	Solubility	Practically insoluble in water; soluble in oils and organic solvents
t½	Biological Half-life	1 day (IM)
⊕	PubChem CID	24822 ↗

Pharmacological Profile
Anabolic Rating	500
Androgenic Rating	500
Aromatization	None
Hepatotoxicity	Low
Detection Time	5 months

Clinical Notes

Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead

19-nor 5alpha-reduced analogue of nandrolone. Non-aromatizable — AR-binding affinity roughly 5x testosterone, with measurable agonist activity at the progesterone receptor. The acetate ester generates fast serum peaks and drops; EOD administration is the floor for stable concentrations. Clinical picture: rapid lean-tissue accretion independent of caloric surplus, reduced adipose mass via direct AR signalling in adipocytes, pronounced lipid shift (HDL suppression 40–60%). Prolactin elevation occurs in a subset — cabergoline 0.25 mg twice weekly is the standard response. Renal biomarkers (creatinine, cystatin C) commonly shift upward; this reflects haem metabolite excretion in urine (brick-red pigment) rather than confirmed nephrotoxicity, but CKD-EPI readings should be interpreted with the confounding documented. Nocturnal sympathetic tone (insomnia, diaphoresis) is dose-dependent and resolves on cessation.

Known trade names: Finajet, Finaplix, Trenbol

External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

Tren Mix 200 mg Vedi Pharma